How Manage Multiple Small Bowel Neuroendocrine Tumors? Abstract #1096

Introduction: Multiple small bowel neuroendocrine tumors (SB-NET) represent 30% of SB-NET.
Aim(s): This retrospective study aimed to compare multiple versus unifocal SB-NET and to describe surgical management of SB-NET.
Materials and methods: All consecutives patients with SB-NET who underwent the resection of at least one primary SB-NET, between 01/01/2000 and 01/01/2013 were analyzed. All morphological workup done before surgery, histological classifications and the lymph node (LN) ratio (LN involved/removed) were recorded.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD, PhD Thomas Walter

To read results and conclusion, please login ...

Further abstracts you may be interested in

#376 Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
Introduction: Small bowel neuroendocrine tumors are uncommon tumors with an incidence of <0.5-1 per 100,000 population/year. We report on the survival rates of patients who had the primary tumor resected, to see whether primary tumor removal improves outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#1410 Predictive Factors for Survival in Patients with Advanced Small Bowel Neuroendocrine Tumours
Introduction: Tumour grade and hepatic metastases are negative prognostic factors for advanced small bowel neuroendocrine tumours (SBNETs), but data assessing other prognosticators at diagnosis (Dx) are lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Christos Toumpanakis
#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs
Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Mark Kidd
#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors
Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Drs. Anela Blazevic
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.